Generic Name and Formulations:
Sinecatechins 15%; oint.
Indications for VEREGEN:
External genital and perianal warts (Condylomata acuminata) in immunocompetent patients.
≥18yrs: Wash hands. Apply ointment to each wart 3 times daily for up to 16 weeks. Do not cover treated area.
<18yrs: not recommended.
Do not use on internal or mucous membrane warts or on broken skin. Caution with tampon insertion (avoid inadvertent internal application). Wash ointment off if severe reaction occurs. Avoid sexual contact with ointment on skin. Immunosuppressed. May stain fabrics. Avoid sun, UV light on treated area. Pregnancy (Cat.C). Nursing mothers.
Concomitant use of condoms or diaphragm: not recommended (ointment may weaken rubber).
Local reactions (eg, erythema, erosion, edema, itching, burning), phimosis, inguinal lymphadenitis, urethral meatal stenosis, dysuria, rash, desquamation, bleeding, hypersensitivity, superinfection.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib